: +1 844-445-3653 : cs@compliancegrowth.com
Peter Calcott Ph.D.
Peter Calcott Ph.D.
Investigating Out of Specification (OOS) Test Results in the Laboratory FDA Guidance and Latest Expectations
Pharmaceutical
Live Webinar
Jun 30, 2026 , 01 : 00 PM ET

71 Days Left
 118 Minutes
Description

Inadequate investigation of out-of-specification (OOS) results in the laboratory is a common observation cited in FDA 483s and Warning Letters. Regulatory investigators worldwide are closely scrutinizing laboratory operations, and FDA includes OOS investigations as a quality metric. Failure to investigate OOS results appropriately can constitute a data integrity issue—for example, retesting without justification, cherry-picking data, or “experimental” testing prior to GMP release testing. Establishing a clear, defined strategy before encountering an OOS is critical for compliance.

This live webinar will provide a detailed understanding of how a compliant laboratory manages testing and OOS investigations, and how laboratories interact with other functional units during the process. It will outline FDA guidance on handling OOS results and provide a clear process for compliant laboratory operations. Real-world examples from Chemistry and Microbiology in QC and manufacturing testing will also be discussed.

This Live Webinar Will Cover

  • Setting up a compliant laboratory
  • Requirements for laboratory OOS investigations
  • Latest regulatory expectations
  • Laboratory OOS investigation process
  • Phase I investigations
  • Phase II investigations
  • Retesting and resampling
  • Communicating with QA and other departments

Learning Benefits

  • Understand what a compliant laboratory looks like
  • Recognize regulatory expectations for OOS investigations
  • Learn the expectation for root cause identification in OOS results
  • Gain a clear understanding of the OOS investigation process
  • Learn key terminology associated with OOS investigations
  • Understand outlier testing
  • See how OOS investigations align with deviation investigation expectations

Regulations and Guidances Covered

  • US – 21 CFR 211.160, 192
  • ICH Q7; 11.1
  • FDA Guidance for Industry: Investigating OOS Test Results for Pharmaceutical Production

Who Should Attend

  • Senior Management
  • Quality Assurance
  • Quality Control Operations
  • Regulatory Affairs
  • Regulatory Compliance
  • QA Product Reviewers
  • Production Management
Training Options
Error Conference Exists In Wish-list.

Congrats Conference Added In Wish-list.


Total
$0

Peter Calcott Ph.D.

Peter Calcott Ph.D.

Peter H. Calcott, Ph.D. is President, Calcott Consulting which is focused on delivering solutions to pharmaceutical and biotechnology companies in the areas of corporate strategy, supply chain, quality, clinical development, regulatory affairs, corporate compliance and enterprise e-solutions. He is also an Academic Program Developer for the University of California, Berkeley’s Biotechnology and Pharmaceutics Postgraduate Programs. Prior to this he was VP at the executive team level at PDL BioPharma where he was responsible for development and implementation of Quality &...